FDA to publish fiscal year 2015 generic drug user fee rates
PepsiCo, Nature Conservancy announce partnership
PURCHASE, N.Y. — PepsiCo and the Nature Conservancy will unite to help increase recycling and protect drinking water in a new five-year partnership called "Recycle for Nature." PepsiCo will expand the availability or recycling bins in the United States, beginning at gas stations and convenience stoers. According to a PepsiCo survey, recyling recepticles are available only 12% of the time at away-from-home locations.
"Most consumers want to recycle when they're away from home — there just aren't enough convenient places to do it," said Al Carey, CEO of PepsiCo Americas Beverages. "This is a huge opportunity that has been largely unaddressed until now. The easier we can make it to recycle, the more likely people are to recycle; and by giving consumers the added incentive of helping protect our watersheds, we can make an impact."
The partnership also will give consumers a chance to protect drinking water. By recycling with greater frequency, consumers help to drive efforts that protect drinking water in areas that supply drinking water to more than 35 million people. The goal is to save and restore 1 billion gallons of water over five years in rivers that include: Colorado River; Denver's Front Range Forests; the Verde River in Arizona; the Kings River in Northwest Arkansas; and the Cape Fear Rive in North Carolina.
"As our population and economies grow, already-stressed water sources will face unprecedented pressure," said Mark R. Tercek, president and CEO of the Nature Conservancy. "Protecting the rivers that provide clean, reliable water for people, and nature is one of the smartest investments that forward-thinking companies can make."
Generic medicine revenue up 5% for Teva’s Q2
JERUSALEM — Teva Pharmaceuticals on Thursday announced results for second-quarter 2014, which included revenues of $5 billion, an increase of 2% compared with the same period last year.
The company reported non-GAAP operating income of $1.4 billion and GAAP operating income of $295 million. Generic medicine revenues saw an increase of 5%, with U.S. generics sales up by 10%; generic profitability is up by 41%.
“We are pleased with the results of second quarter 2014, delivering organic growth in revenues and all profit lines over the comparable quarter last year. Our generic business delivered solid results with significantly improved profitability. In our specialty business, we have successfully converted, to date, 51% of the Copaxone family in the United States to the newly launched Copaxone 40mg/mL, and are continuing to stably lead the global and U.S. relapsing remitting multiple sclerosis market. We also are excited about the progress we are making in our specialty pipeline, which includes, this quarter, the successful launch of DuoResp Spiromax in Europe, the progression toward FDA submission for ER hydrocodone and the FDA acceptance of our albuterol MDPI NDA," stated Erez Vigodman, president and CEO of Teva.